Abstract

Positive-sense RNA viruses hijack intracellular membranes that provide niches for viral RNA synthesis and a platform for interactions with host proteins. However, little is known about host factors at the interface between replicase complexes and the host cytoplasm. We engineered a biotin ligase into a coronaviral replication/transcription complex (RTC) and identified >500 host proteins constituting the RTC microenvironment. siRNA-silencing of each RTC-proximal host factor demonstrated importance of vesicular trafficking pathways, ubiquitin-dependent and autophagy-related processes, and translation initiation factors. Notably, detection of translation initiation factors at the RTC was instrumental to visualize and demonstrate active translation proximal to replication complexes of several coronaviruses. Collectively, we establish a spatial link between viral RNA synthesis and diverse host factors of unprecedented breadth. Our data may serve as a paradigm for other positive-strand RNA viruses and provide a starting point for a comprehensive analysis of critical virus-host interactions that represent targets for therapeutic intervention.

Data availability

The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD009975.All other data generated or analysed during this study are included in the manuscript and supporting files.

The following data sets were generated

Article and author information

Author details

  1. Philip V'kovski

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8366-1220
  2. Markus Gerber

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Jenna Kelly

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Stephanie Pfaender

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Nadine Ebert

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  6. Sophie Braga Lagache

    Mass Spectrometry and Proteomics Core Facility, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Cedric Simillion

    Mass Spectrometry and Proteomics Core Facility, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  8. Jasmine Portmann

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  9. Hanspeter Stalder

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  10. Véronique Gaschen

    Division Veterinary Anatomy, University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  11. Rémy Bruggmann

    Interfaculty Bioinformatics Unit, University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-4733-7922
  12. Michael H Stoffel

    Division of Veterinary Anatomy, University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4699-5125
  13. Manfred Heller

    Mass Spectrometry and Proteomics Core Facility, Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  14. Ronald Dijkman Dijkman

    Institute of Virology and Immunology IVI, Bern, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Volker Thiel

    Institute of Virology and Immunology IVI, Bern, Switzerland
    For correspondence
    volker.thiel@vetsuisse.unibe.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5783-0887

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (173085)

  • Philip V'kovski
  • Volker Thiel

European Commission (748627)

  • Stephanie Pfaender
  • Volker Thiel

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (160780)

  • Jenna Kelly
  • Nadine Ebert
  • Volker Thiel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Karla Kirkegaard, Stanford University School of Medicine, United States

Version history

  1. Received: September 14, 2018
  2. Accepted: January 11, 2019
  3. Accepted Manuscript published: January 11, 2019 (version 1)
  4. Version of Record published: February 12, 2019 (version 2)

Copyright

© 2019, V'kovski et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 10,951
    views
  • 1,632
    downloads
  • 137
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Philip V'kovski
  2. Markus Gerber
  3. Jenna Kelly
  4. Stephanie Pfaender
  5. Nadine Ebert
  6. Sophie Braga Lagache
  7. Cedric Simillion
  8. Jasmine Portmann
  9. Hanspeter Stalder
  10. Véronique Gaschen
  11. Rémy Bruggmann
  12. Michael H Stoffel
  13. Manfred Heller
  14. Ronald Dijkman Dijkman
  15. Volker Thiel
(2019)
Determination of host proteins composing the microenvironment of coronavirus replicase complexes by proximity-labeling
eLife 8:e42037.
https://doi.org/10.7554/eLife.42037

Share this article

https://doi.org/10.7554/eLife.42037

Further reading

    1. Microbiology and Infectious Disease
    Hina Khan, Partha Paul ... Dibyendu Sarkar
    Research Article

    Survival of Mycobacterium tuberculosis within the host macrophages requires the bacterial virulence regulator PhoP, but the underlying reason remains unknown. 3′,5′-Cyclic adenosine monophosphate (cAMP) is one of the most widely used second messengers, which impacts a wide range of cellular responses in microbial pathogens including M. tuberculosis. Herein, we hypothesized that intra-bacterial cAMP level could be controlled by PhoP since this major regulator plays a key role in bacterial responses against numerous stress conditions. A transcriptomic analysis reveals that PhoP functions as a repressor of cAMP-specific phosphodiesterase (PDE) Rv0805, which hydrolyzes cAMP. In keeping with these results, we find specific recruitment of the regulator within the promoter region of rv0805 PDE, and absence of phoP or ectopic expression of rv0805 independently accounts for elevated PDE synthesis, leading to the depletion of intra-bacterial cAMP level. Thus, genetic manipulation to inactivate PhoP-rv0805-cAMP pathway decreases cAMP level, stress tolerance, and intracellular survival of the bacillus.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Natalia E Ketaren, Fred D Mast ... John D Aitchison
    Research Advance

    To date, all major modes of monoclonal antibody therapy targeting SARS-CoV-2 have lost significant efficacy against the latest circulating variants. As SARS-CoV-2 omicron sublineages account for over 90% of COVID-19 infections, evasion of immune responses generated by vaccination or exposure to previous variants poses a significant challenge. A compelling new therapeutic strategy against SARS-CoV-2 is that of single-domain antibodies, termed nanobodies, which address certain limitations of monoclonal antibodies. Here, we demonstrate that our high-affinity nanobody repertoire, generated against wild-type SARS-CoV-2 spike protein (Mast et al., 2021), remains effective against variants of concern, including omicron BA.4/BA.5; a subset is predicted to counter resistance in emerging XBB and BQ.1.1 sublineages. Furthermore, we reveal the synergistic potential of nanobody cocktails in neutralizing emerging variants. Our study highlights the power of nanobody technology as a versatile therapeutic and diagnostic tool to combat rapidly evolving infectious diseases such as SARS-CoV-2.